{"id":"placebo-oxaliplatin","safety":{"commonSideEffects":[{"rate":"76","effect":"Peripheral neuropathy"},{"rate":"64","effect":"Nausea and vomiting"},{"rate":"46","effect":"Diarrhea"},{"rate":"61","effect":"Fatigue"},{"rate":"41","effect":"Neutropenia"},{"rate":"28","effect":"Thrombocytopenia"},{"rate":"72","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxaliplatin is a third-generation platinum compound that binds to DNA and forms interstrand and intrastrand crosslinks, preventing DNA synthesis and triggering apoptosis in cancer cells. It is often used in combination chemotherapy regimens, particularly for colorectal cancer. The drug has a different spectrum of activity and toxicity profile compared to earlier platinum agents like cisplatin.","oneSentence":"Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to inhibit cancer cell replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:25.753Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (in combination with fluorouracil and leucovorin)"},{"name":"Adjuvant treatment of stage III colon cancer"}]},"trialDetails":[{"nctId":"NCT07174947","phase":"PHASE2","title":"SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10-01","conditions":"Hepatobiliary Malignancy, Fluoxetine, Anxiety Disorders","enrollment":240},{"nctId":"NCT07409272","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2026-02-17","conditions":"Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":614},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT06692907","phase":"PHASE2","title":"Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-03-31","conditions":"Escherichia Infection","enrollment":72},{"nctId":"NCT06256328","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2024-01-10","conditions":"Gastric Cancer","enrollment":226},{"nctId":"NCT06901531","phase":"PHASE3","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-05-22","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":500},{"nctId":"NCT03221426","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":1007},{"nctId":"NCT04882241","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":120},{"nctId":"NCT03675737","phase":"PHASE3","title":"Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-11-08","conditions":"Stomach Neoplasms","enrollment":1579},{"nctId":"NCT06532006","phase":"PHASE3","title":"A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2024-11-22","conditions":"Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer","enrollment":550},{"nctId":"NCT05052801","phase":"PHASE3","title":"Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2022-03-07","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":547},{"nctId":"NCT07409428","phase":"PHASE3","title":"A Phase III Study of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Relapsed/Refractory DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Hutchmed","startDate":"2026-03-10","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":240},{"nctId":"NCT03504397","phase":"PHASE3","title":"A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-06-21","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":565},{"nctId":"NCT07113275","phase":"PHASE3","title":"A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in High-Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tao Zhang","startDate":"2026-02-11","conditions":"Rectal Cancer, Total Neoadjuvant Therapy, Radiotherapy","enrollment":435},{"nctId":"NCT07023315","phase":"PHASE3","title":"A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-08-14","conditions":"Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma","enrollment":760},{"nctId":"NCT03362177","phase":"PHASE3","title":"Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-09-30","conditions":"Chemotherapy-induced Thrombocytopenia","enrollment":165},{"nctId":"NCT07391163","phase":"NA","title":"Protective Effect of N-acetylcysteine on Oxaliplatin-Induced Neuropathy in Colorectal Cancer","status":"COMPLETED","sponsor":"Tanta University","startDate":"2024-01-01","conditions":"Colorectal Cancer","enrollment":46},{"nctId":"NCT03653507","phase":"PHASE3","title":"A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-11-28","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":507},{"nctId":"NCT05700448","phase":"PHASE3","title":"Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"CStone Pharmaceuticals","startDate":"2026-06","conditions":"Extranodal NK/T-cell Lymphoma","enrollment":150},{"nctId":"NCT06206733","phase":"PHASE3","title":"ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AskGene Pharma, Inc.","startDate":"2024-01-25","conditions":"Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma","enrollment":780},{"nctId":"NCT04137107","phase":"PHASE2, PHASE3","title":"Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2020-06-17","conditions":"Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8","enrollment":220},{"nctId":"NCT07320950","phase":"PHASE3","title":"Neuroprotective Effect of Neurotropin on Chronic OXA-induced Neurotoxicity in Stage II and Stage III CRC Patients","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2022-04-01","conditions":"Colorectal Cancer","enrollment":333},{"nctId":"NCT04592913","phase":"PHASE3","title":"Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-11-17","conditions":"Gastrointestinal Neoplasms, Esophagogastric Junction","enrollment":957},{"nctId":"NCT06576921","phase":"PHASE2","title":"Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2024-11-15","conditions":"Stomach Neoplasms, Immune Checkpoint Inhibitors","enrollment":116},{"nctId":"NCT06093425","phase":"PHASE3","title":"Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Transcenta Therapeutics Co., Ltd.","startDate":"2026-06-30","conditions":"Gastric Cancer, Gastroesophageal-junction Cancer, Advanced Cancer","enrollment":820},{"nctId":"NCT05111626","phase":"PHASE3","title":"Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2022-03-14","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":515},{"nctId":"NCT03615326","phase":"PHASE3","title":"Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-05","conditions":"Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma","enrollment":738},{"nctId":"NCT05025826","phase":"NA","title":"Study Evaluating Neurotoxicity in Patients With Metastatic Gastro Intestinal Cancer Taking Phycocare® or Placebo During Oxaliplatin Based Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2022-04-01","conditions":"Metastatic Gastric Cancer","enrollment":110},{"nctId":"NCT05008783","phase":"PHASE3","title":"A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma","status":"COMPLETED","sponsor":"Akeso","startDate":"2021-09-17","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":610},{"nctId":"NCT07191405","phase":"NA","title":"Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-09-18","conditions":"Immunotherapy, Chemotherapy","enrollment":156},{"nctId":"NCT05149807","phase":"PHASE2, PHASE3","title":"Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer","status":"TERMINATED","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2022-01-26","conditions":"Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer","enrollment":81},{"nctId":"NCT07132008","phase":"PHASE3","title":"Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2025-10-01","conditions":"Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors","enrollment":94},{"nctId":"NCT00680901","phase":"PHASE3","title":"LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-06-04","conditions":"Neoplasms, Gastrointestinal Tract","enrollment":545},{"nctId":"NCT03783442","phase":"PHASE3","title":"A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2018-12-11","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":649},{"nctId":"NCT06949033","phase":"PHASE3","title":"Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Zuoyi Jiao","startDate":"2025-05-15","conditions":"Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy","enrollment":668},{"nctId":"NCT07028424","phase":"PHASE2","title":"PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment","status":"NOT_YET_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2025-07","conditions":"PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":206},{"nctId":"NCT06055179","phase":"NA","title":"XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)","status":"RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2024-03-08","conditions":"Xiao Chai Hu Tang, Irinotecan-induced Diarrhea","enrollment":98},{"nctId":"NCT07025239","phase":"PHASE3","title":"QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-07","conditions":"Metastatic Colorectal Cancer","enrollment":430},{"nctId":"NCT06601504","phase":"PHASE2","title":"Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hutchmed","startDate":"2024-11-05","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":61},{"nctId":"NCT05712356","phase":"PHASE2","title":"A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lisata Therapeutics, Inc.","startDate":"2023-08-24","conditions":"Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma","enrollment":67},{"nctId":"NCT05201352","phase":"PHASE1, PHASE2","title":"Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Georges Francois Leclerc","startDate":"2022-10-13","conditions":"Metastatic Colorectal Cancer","enrollment":160},{"nctId":"NCT04856787","phase":"PHASE2, PHASE3","title":"A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC","status":"TERMINATED","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2021-06-22","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":62},{"nctId":"NCT05624138","phase":"PHASE3","title":"The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy","status":"RECRUITING","sponsor":"Tanta University","startDate":"2022-11-09","conditions":"Neuropathy;Peripheral","enrollment":64},{"nctId":"NCT04245865","phase":"PHASE2","title":"Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vejle Hospital","startDate":"2020-06-26","conditions":"Colorectal Cancer Metastatic","enrollment":83},{"nctId":"NCT03722680","phase":"PHASE2","title":"Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy.","status":"SUSPENDED","sponsor":"UNICANCER","startDate":"2020-10-28","conditions":"Oxaliplatin-induced Peripheral Neuropathy","enrollment":80},{"nctId":"NCT05342194","phase":"PHASE3","title":"Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2023-06-19","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":480},{"nctId":"NCT06850454","phase":"PHASE3","title":"Olanzapine Versus Placebo for Moderately Emetogenic Chemotherapy","status":"RECRUITING","sponsor":"Mahidol University","startDate":"2025-01-10","conditions":"Chemotherapy Induced Nausea and Vomiting","enrollment":140},{"nctId":"NCT06405113","phase":"PHASE2","title":"FMT+SOX+Sintilimab As First-line Treatment for Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Changzhou No.2 People's Hospital","startDate":"2024-06-01","conditions":"Gastric Cancer","enrollment":198},{"nctId":"NCT03777657","phase":"PHASE3","title":"Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2018-12-13","conditions":"Gastric, or Gastroesophageal Junction Adenocarcinoma","enrollment":997},{"nctId":"NCT05291286","phase":"EARLY_PHASE1","title":"BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients","status":"COMPLETED","sponsor":"Bexion Pharmaceuticals, Inc.","startDate":"2022-10-17","conditions":"Neuropathy;Peripheral, Chemotherapy-induced Peripheral Neuropathy","enrollment":21},{"nctId":"NCT05180734","phase":"PHASE3","title":"PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2022-02-10","conditions":"Gastric or Esophagogastric Junction Adenocarcinoma","enrollment":878},{"nctId":"NCT06128252","phase":"NA","title":"Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2024-09-01","conditions":"Gastric Cancer","enrollment":96},{"nctId":"NCT02581215","phase":"PHASE2","title":"Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Walid Shaib, MD","startDate":"2016-09-11","conditions":"Pancreatic Cancer","enrollment":84},{"nctId":"NCT03122886","phase":"NA","title":"Fat Emulsion in Preventing Hypersensitivity Reactions in Patients With Cancer Receiving Carboplatin or Oxaliplatin","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-07-14","conditions":"Advanced Malignant Neoplasm","enrollment":19},{"nctId":"NCT06725043","phase":"NA","title":"Ultrasound Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Colorectal Cancer Patients","status":"COMPLETED","sponsor":"Cairo University","startDate":"2023-07-01","conditions":"Colorectal Cancer Patients and Their Partners, Oxaliplatin-induced Peripheral Neuropathy","enrollment":60},{"nctId":"NCT06722950","phase":"PHASE2","title":"Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral Neuropathy","status":"NOT_YET_RECRUITING","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2024-12","conditions":"Colorectal Adenoma","enrollment":120},{"nctId":"NCT04607668","phase":"PHASE3","title":"Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):","status":"TERMINATED","sponsor":"G1 Therapeutics, Inc.","startDate":"2021-01-06","conditions":"Colorectal Cancer Metastatic, Myelosuppression-Adult, Chemotherapeutic Toxicity","enrollment":326},{"nctId":"NCT04210115","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-28","conditions":"Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)","enrollment":703},{"nctId":"NCT03941093","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2019-05-10","conditions":"Pancreatic Cancer Non-resectable","enrollment":284},{"nctId":"NCT02705300","phase":"PHASE2","title":"Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Vejle Hospital","startDate":"2016-05-06","conditions":"Colorectal Cancer","enrollment":70},{"nctId":"NCT06349044","phase":"NA","title":"A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-03-20","conditions":"Her-2 Negative Adenocarcinoma of the Gastro-oesophageal Junction/Gastric Adenocarcinoma, Hepatocellular Carcinoma, Biliary Tract Carcinoma","enrollment":120},{"nctId":"NCT05251727","phase":"PHASE1","title":"Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients","status":"TERMINATED","sponsor":"Veloxis Pharmaceuticals","startDate":"2022-03-24","conditions":"Chemotherapy-induced Peripheral Neuropathy","enrollment":77},{"nctId":"NCT06509880","phase":"PHASE1, PHASE2","title":"Immunosurveillance for Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"MIPO Clinic","startDate":"2024-07-15","conditions":"Monitoring, Immunologic","enrollment":200},{"nctId":"NCT02746796","phase":"PHASE2, PHASE3","title":"Study of ONO-4538 in Gastric Cancer","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2016-03","conditions":"Gastric Cancer","enrollment":680},{"nctId":"NCT03006705","phase":"PHASE3","title":"Study of Adjuvant ONO-4538 With Resected Gastric Cancer","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2017-01-31","conditions":"Gastric Cancer","enrollment":800},{"nctId":"NCT02889666","phase":"PHASE1","title":"A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2008-01","conditions":"Recurrent Non-small Cell Lung Cancer","enrollment":500},{"nctId":"NCT04908813","phase":"PHASE2","title":"Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2021-09-29","conditions":"Gastric Cancer","enrollment":150},{"nctId":"NCT05254639","phase":"PHASE2","title":"Donepezil for Oxaliplatin-induced Neuropathy Peripheral Neuropathy: Proof of Concept Study","status":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2022-06-02","conditions":"Digestive Oncology, Supportive Care","enrollment":77},{"nctId":"NCT04431258","phase":"PHASE1, PHASE2","title":"ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study","status":"COMPLETED","sponsor":"Ability Pharmaceuticals SL","startDate":"2021-05-06","conditions":"Pancreatic Cancer","enrollment":150},{"nctId":"NCT06177041","phase":"PHASE3","title":"M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.","status":"RECRUITING","sponsor":"FutureGen Biopharmaceutical (Beijing) Co., Ltd","startDate":"2023-12-25","conditions":"Locally Advanced Unresectable or Metastatic Gastric Cancer, Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma","enrollment":486},{"nctId":"NCT03694522","phase":"PHASE2","title":"A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer","status":"COMPLETED","sponsor":"Five Prime Therapeutics, Inc.","startDate":"2018-09-14","conditions":"Gastric Cancer","enrollment":155},{"nctId":"NCT06192186","phase":"PHASE4","title":"Adebrelimab Combined With SOX Regimen in Preoperative Neoadjuvant Transformation Therapy for Locally Advanced Gastric Adenocarcinoma","status":"UNKNOWN","sponsor":"Yang Jianjun, PhD","startDate":"2023-12-30","conditions":"Locally Advanced Gastric Adenocarcinoma","enrollment":110},{"nctId":"NCT05872685","phase":"PHASE2","title":"Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)","status":"RECRUITING","sponsor":"Yu jiren","startDate":"2023-12-24","conditions":"Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Proficient Mismatch Repair","enrollment":314},{"nctId":"NCT03802591","phase":"PHASE3","title":"A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma","status":"COMPLETED","sponsor":"CStone Pharmaceuticals","startDate":"2019-03-28","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":479},{"nctId":"NCT05908838","phase":"EARLY_PHASE1","title":"Clinical Study of Modified Banxia Xiexin Decoction Treatment on Gastric Cancer","status":"COMPLETED","sponsor":"ShuGuang Hospital","startDate":"2017-01-01","conditions":"Gastric Cancer (Diagnosis)","enrollment":146},{"nctId":"NCT04233151","phase":"PHASE3","title":"QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2020-01-20","conditions":"Metastatic Colorectal Cancer","enrollment":590},{"nctId":"NCT02344810","phase":"PHASE1, PHASE2","title":"C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer","status":"WITHDRAWN","sponsor":"Eastern Cooperative Oncology Group","startDate":"2015-03-06","conditions":"Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach","enrollment":""},{"nctId":"NCT05866653","phase":"PHASE2","title":"Effect of Lidocaine Transdermal Patch as Add-On Therapy in Treatment of Oxaliplatin Induced Peripheral Neuropathy in Colorectal Cancer Patients","status":"UNKNOWN","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-03-25","conditions":"Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients","enrollment":90},{"nctId":"NCT05834231","phase":"PHASE1, PHASE2","title":"Efficacy of Memantine in Prevention of Oxaliplatin-induced Peripheral Neurotoxicity","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2023-08","conditions":"Cancer","enrollment":60},{"nctId":"NCT00430313","phase":"NA","title":"Effects of Acupoint Electro-stimulation on Preventing Nausea and Vomiting Induced by Cisplatin or Oxaliplatin","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-01-04","conditions":"Liver Cancer, Liver Metastasis","enrollment":""},{"nctId":"NCT03745170","phase":"PHASE3","title":"Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2018-12-19","conditions":"Gastric Cancer","enrollment":650},{"nctId":"NCT01099449","phase":"PHASE3","title":"Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2010-06","conditions":"Chemotherapeutic Agent Toxicity, Colorectal Cancer, Neuropathy","enrollment":362},{"nctId":"NCT05590117","phase":"EARLY_PHASE1","title":"Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2022-10-11","conditions":"Colo-rectal Cancer, Neuropathy;Peripheral, Mucositis","enrollment":48},{"nctId":"NCT01150045","phase":"PHASE3","title":"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery","status":"UNKNOWN","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2010-06","conditions":"Colorectal Cancer","enrollment":2527},{"nctId":"NCT04282590","phase":"PHASE2","title":"A Study to Investigate the Safety and Efficacy of TRK-750 for the Treatment of Patients With CIPN (Chopin Study)","status":"WITHDRAWN","sponsor":"Toray Industries, Inc","startDate":"2020-04","conditions":"Chemotherapy-induced Peripheral Neuropathy","enrollment":""},{"nctId":"NCT03254394","phase":"PHASE1, PHASE2","title":"Lidocaine for Oxaliplatin-induced Neuropathy","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-09-15","conditions":"Neuropathy, Painful, Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer","enrollment":26},{"nctId":"NCT02539225","phase":"PHASE2","title":"A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-10-05","conditions":"Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":191},{"nctId":"NCT01896531","phase":"PHASE2","title":"A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2013-08-14","conditions":"Gastric Cancer","enrollment":153},{"nctId":"NCT04492436","phase":"PHASE2","title":"A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo","status":"WITHDRAWN","sponsor":"Veloxis Pharmaceuticals","startDate":"2021-10","conditions":"Chemotherapy-induced Peripheral Neuropathy","enrollment":""},{"nctId":"NCT03130790","phase":"PHASE2, PHASE3","title":"Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)","status":"COMPLETED","sponsor":"ASLAN Pharmaceuticals","startDate":"2017-08-31","conditions":"Gastric Cancer","enrollment":52},{"nctId":"NCT04034355","phase":"PHASE3","title":"Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer","status":"TERMINATED","sponsor":"Egetis Therapeutics","startDate":"2019-01-07","conditions":"Colorectal Cancer, Chemotherapy-induced Peripheral Neuropathy","enrollment":301},{"nctId":"NCT03654729","phase":"PHASE3","title":"Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)","status":"TERMINATED","sponsor":"Egetis Therapeutics","startDate":"2018-11-07","conditions":"Colorectal Cancer, Chemotherapy-induced Peripheral Neuropathy","enrollment":291},{"nctId":"NCT04859582","phase":"PHASE3","title":"Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-11-08","conditions":"Stomach Neoplasms","enrollment":""},{"nctId":"NCT01505166","phase":"PHASE2","title":"Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases","status":"TERMINATED","sponsor":"Gradalis, Inc.","startDate":"2012-03","conditions":"Colon Cancer","enrollment":3},{"nctId":"NCT04947826","phase":"PHASE2","title":"Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor Thrombosis","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-08","conditions":"Hepatocellular Carcinoma With Major Portal Vein Thrombosis","enrollment":100},{"nctId":"NCT04136600","phase":"PHASE2","title":"EGFR Monoclonal Antibody for Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Shanghai Changzheng Hospital","startDate":"2019-07-01","conditions":"Gastric Cancer, Cetuximab, Nimotuzumab","enrollment":100},{"nctId":"NCT04690283","phase":"PHASE3","title":"Yiqi Wenjing Prescriptions Preventive Efficacy of Oxaliplatin-induced Peripheral Neuropathy Clinical Trial","status":"UNKNOWN","sponsor":"Nanjing NingQi Medicine Science and Technology Co., Ltd.","startDate":"2021-01-01","conditions":"Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer","enrollment":360},{"nctId":"NCT02135887","phase":"","title":"A Trial of MB-6 for Reduction of Neutropenia Induced by Chemotherapy in Patients With Stage III Colorectal Cancer.","status":"UNKNOWN","sponsor":"Microbio Co Ltd","startDate":"2013-11-04","conditions":"Stage III Colorectal Cancer, Neutropenia","enrollment":184},{"nctId":"NCT04521491","phase":"NA","title":"A Trial of Adjuvant Therapy After Hepatocarcinoma Resection Based on Folate Receptor-positive Circulating Tumor Cells","status":"UNKNOWN","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2020-12-01","conditions":"Hepatocellular Carcinoma","enrollment":184},{"nctId":"NCT04337879","phase":"PHASE1, PHASE2","title":"A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-07-20","conditions":"Advanced Colorectal Cancer","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":238,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo , Oxaliplatin","genericName":"Placebo , Oxaliplatin","companyName":"University of Sao Paulo","companyId":"university-of-sao-paulo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to inhibit cancer cell replication. Used for Metastatic colorectal cancer (in combination with fluorouracil and leucovorin), Adjuvant treatment of stage III colon cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}